FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron's COVID-19 Antibody Cocktail

  • The FDA has authorized a new, lower-dose version of Regeneron Pharmaceuticals Inc’s REGN COVID-19 monoclonal antibody cocktail for those with COVID-19 who are at high risk of progressing to hospitalization.
  • The agency updated the Emergency Use Authorization (EUA) for REGEN-COV, lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab),
  • Regeneron said in a statement that the combo “should be administered by intravenous (IV) infusion” and subcutaneous injections “are an alternative when IV infusion is not feasible and would lead to a delay in treatment.”
  • The EUA is supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70%
  • In addition, in vitro research has shown that REGEN-COV retains potency against the main variants of concern circulating within the U.S., including the P.1 variant and the B.1.351 variant.
  • Later this summer, Regeneron expects to submit a full marketing application for the combo treatment for the same indication in non-hospitalized outpatients with COVID-19.
  • In addition to outpatients, REGEN-COV is also being evaluated in prevention and certain hospitalized COVID-19 patient settings.
  • Price Action: REGN shares are up 2.33% at $517.43 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsCovid-19COVID-19 VaccineEmergency Use Authorization
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!